Charles River is the Drug Discovery partner of choice with the industry’s most comprehensive service portfolio and expertise.
We are an organisation that takes joy in drug discovery and through a wealth of experience delivers success for our partner organisations. We have discovered over 80 pre-clinical candidates of which at least 25% have progressed to clinical PoC ; 6 are currently in phase III and Belinostat is now on the market.
We provide drug discovery services to the bioscience community and these collaborations cover the spectrum from small, single discipline projects to fully integrated drug discovery projects. Our Early Discovery DMPK scientists, chemists and biologists work very closely with colleagues in in vivo pharmacology and safety to drive projects to ultimate goals. We have worked across all major druggable target classes and therapeutic areas and a range of rare and neglected diseases with in- depth experience in CNS and oncology.
Historically, our work was largely based around small molecules we have run around 300 small molecule projects in H2L and LO. More recently we have increased our work in large molecules – e.g. ASO, CAR-T and antibodies. Our major capabilties include
- Cell line generation, Customised assay development, Biomarker development, High-throughput screening, Automated electrophysiology, Compound profiling, Primary cell screening, Structural biology, Fragment screening, Stem cells and proteomics.
- Synthetic and medicinal chemistry with a particular experience in complex chemistry and problem solving, analytical and purification both achiral and chiral, scale up chemistry, pharmaceutics and formulations, computational chemistry and cheminformatics, support for intellectual property generation, and green chemistry.
- DMPK - supports in vitro ADME screening, metabolite identification, bioanalysis, PK/PD analysis, high throughput mass spec analysis, customised work packages to address specific question across different industries.
There are currently no jobs.